NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial<
25 May 2023

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

Funding to obtain IND approval for its lead compound VMX-C001 and to complete preparations for the pivotal clinical trial
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors<
23 May 2023

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis<
23 May 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

The study is designed to investigate the safety and efficacy of GB0139 in patients with IPF
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023<
22 May 2023

SparingVision Presents New Data on SPVN20 Program at ASGCT 2023

First oral presentation on SPVN20 in a major scientific and medical conference

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update<
16 May 2023

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with uncontrolled or resistant hypertension in April 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference<
15 May 2023

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

Elisabet de los Pinos, will participate in a fireside chat at the JMP Securities Life Sciences Conference
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights<
12 May 2023

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

U.S. Food and Drug Administration (FDA) Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma
Babyscripts and MemorialCare Mark Three-year Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations<
11 May 2023

Babyscripts and MemorialCare Mark Three-year Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations

Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update<
10 May 2023

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Awarded $15 million grant from CIRM to support the KPI-012 PCED program
Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve<
03 May 2023

Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve

Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.